Dr. Kathleen Anne Welsh-Bohmer, a specialist in Alzheimer’s Disease research, has joined the scientific leadership team at NeuroCog Trials (NCT) as the Vice President of Neurodegenerative Disorders. In her new role she will lead the development of new technology and tools to support customers conducting clinical trials for dementia and other cognitive disorders.
Having dedicated more than 25 years to research surrounding neurodegenerative disorders that occur later in life, Dr. Welsh-Bohmer is a Professor of Psychiatry and Neurology at Duke University. She has the highest level of scientific expertise and continues to develop prevention and treatment strategies that help to eliminate the onset of age-related cognitive disorders.
“Seen as one of the most challenging areas of drug development, the Alzheimer’s treatment and prevention landscape requires quickly evolving regulatory guidance”
Her work includes neuropsychology leadership in the Takeda Pharmaceutical’s TOMMORROW STUDY, Phase 3 clinical trial with a focus on the secondary prevention of mild cognitive impairment (MCI) due to AD. The methods her team developed for this study filled an information void and led to the validation of a genetic biomarker that will help to accelerate global clinical trials in AD prevention.
As part of her new role she will also lead the ongoing development of wearables and custom in-house assessments to support sponsor companies conducting clinical trials related to this therapeutic area.
Dr. Welsh-Bohmer’s work as Director of the Joseph and Kathleen Bryan Alzheimer’s Disease Research Center (Bryan ADRC) at Duke University Medical Center was centred around discovering the biological basis of Alzheimer’s disease and developing methods to enhance early diagnosis and speed drug discovery. She also serves as the Director of Alzheimer’s Disease Clinical Trials within the Duke Clinical Research Institute.
Dr. Richard Keefe, Co-Founder and CEO of NeuroCog Trials, said: “Seen as one of the most challenging areas of drug development, the Alzheimer’s treatment and prevention landscape requires quickly evolving regulatory guidance and disruptive therapeutic approaches. As one of the true leaders in the AD scientific research field, Dr. Welsh-Bohmer brings that expertise to our team and our clients’ projects.”